Many drugs such as Sirolimus, Torin1 and PP242 have also been developed to target mTOR, as well as its downstream pathway, with the aim of targeting various cancers, diabetes, neurodegenerative diseases and aging [4–8]. The gene discussed is MTOR; the disease is cancer.